HighTower Advisors’s Neurogene NGNE Stock Holding History

HighTower Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-2,420	Closed	-$40K	–	3694
2023 Q2	$40K	Hold	2,420	–	–	﹤0.01%	3185
2023 Q1	$34K	Hold	2,420	–	–	﹤0.01%	3094
2022 Q4	$25K	Buy	+2,420	New	+$25K	﹤0.01%	3110
2017 Q1	–	Sell	-2,539	Closed	-$839K	–	2135
2016 Q4	$839K	Buy	2,539 +1,589	+167%	+$427K	0.01%	1044
2016 Q3	$257K	Buy	+950	New	+$191K	﹤0.01%	1525

Other funds holding NGNE

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HighTower Advisors's NGNE Position: Q3 2023 in Review

HighTower Advisors sold out of Neurogene (NGNE) in Q3 2023, closing a stake of 2,420 shares — an estimated $40K sold.

HighTower Advisors first reported a position in NGNE in Q3 2016 and held it in 5 quarters. The position peaked at $839K in Q4 2016. 31 funds tracked by Wall St. Rank hold NGNE as of Q3 2023.

HighTower Advisors reported no remaining Neurogene position as of Q3 2023 after selling out during the quarter.
HighTower Advisors sold 2,420 Neurogene shares in Q3 2023, an estimated $40K.
HighTower Advisors first reported a position in Neurogene in Q3 2016 and held it in 5 quarters.
HighTower Advisors's Neurogene position peaked at $839K in Q4 2016.
31 funds tracked by Wall St. Rank held Neurogene as of Q3 2023.

Based on HighTower Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.